The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Asymmetric Dimethylarginine Plasma Concentrations Differ in Patients with End-Stage Renal Disease: Relationship to Treatment Method and Atherosclerotic Disease
Abstract
Abstract.: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide (NO) synthase. Its concentration is elevated in patients with end-stage renal disease (ESRD), in part because it is excreted via the kidneys. In this study, the plasma concentrations of ADMA, symmetric dimethylarginine, and L-arginine were determined in relation to plasma nitrate levels (as an index of NO formation) for a group of 80 patients with ESRD. The effects of two treatment methods, i.e., hemodialysis (HD) and peritoneal dialysis (PD), and the role of the presence of atherosclerotic disease were evaluated. Forty-three patients receiving HD and 37 patients receiving PD were compared with healthy control subjects. Plasma L-arginine and dimethylarginine levels were determined by HPLC, using precolumn derivatization with o-phthaldialdehyde. Plasma nitrate levels were determined by gas chromatography-mass spectrometry. Predialysis ADMA concentrations in HD-treated patients were approximately sixfold higher than those in the control group (6.0 ± 0.5 versus 1.0 ± 0.1 μmol/L; P < 0.05). Plasma nitrate concentrations were significantly lower in HD-treated patients, which suggests that ADMA may inhibit NO synthase. In contrast, plasma ADMA levels and nitrate concentrations in PD-treated patients were similar to those in control subjects. Plasma L-arginine concentrations were not significantly decreased in patients with ESRD. ADMA concentrations were significantly decreased 5 h after HD, compared with baseline values. ADMA levels were significantly higher in HD-treated patients with manifest atherosclerotic disease than in HD-treated patients without atherosclerotic disease (7.31 ± 0.70 versus 3.95 ± 0.52 μmol/L; P < 0.05). This study confirms that ADMA is accumulated in ESRD. PD-treated patients exhibit significantly lower ADMA levels than do HD-treated patients. Accumulation of ADMA may be a risk factor for the development of endothelial dysfunction and cardiovascular disease in patients with ESRD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The L-Arginine-Nitric Oxide Pathway
Epstein, F. H., Moncada, S., & Higgs, A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292706 · Cited by 6,678
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
Leone, A., Moncada, S., Vallance, P., Calver, A., & Collier, J. (1992) · The Lancet · doi:10.1016/0140-6736(92)90865-z · Cited by 2,107
Accelerated Atherosclerosis in Prolonged Maintenance Hemodialysis
Lindner, A., Charra, B., Sherrard, D. J., & Scribner, B. H. (1974) · New England Journal of Medicine · doi:10.1056/nejm197403282901301 · Cited by 1,776
Böger, R. H., Bode-Böger, S. M., Szuba, A., Tsao, P. S., Chan, J. R., Tangphao, O., Blaschke, T. F., & Cooke, J. P. (1998) · Circulation · doi:10.1161/01.cir.98.18.1842 · Cited by 1,181
Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions.
Förstermann, U., Closs, E. I., Pollock, J. S., Nakane, M., Schwarz, P., Gath, I., & Kleinert, H. (1994) · Hypertension · doi:10.1161/01.hyp.23.6.1121 · Cited by 1,111
Rees, D. D., Palmer, R. M. J., Hodson, H. F., & Moncada, S. (1989) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1989.tb11833.x · Cited by 850
Baylis, C., Mitruka, B., & Deng, A. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115849 · Cited by 729
Cayatte, A. J., Palacino, J. J., Horten, K., & Cohen, R. A. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.5.753 · Cited by 493
Böger, R. H., Bode-Böger, S. M., Thiele, W., Junker, W., Alexander, K., & Frölich, J. C. (1997) · Circulation · doi:10.1161/01.cir.95.8.2068 · Cited by 490
Endogenous Dimethylarginine as an Inhibitor of Nitric Oxide Synthesis
Vallance, P., Leone, A., Calver, A., Collier, J., & Moncada, S. (1992) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199204002-00018 · Cited by 469
Cited by
Zoccali, C., Bode-Böger, S. M., Mallamaci, F., Benedetto, F. A., Tripepi, G., Malatino, L. S., Cataliotti, A., Bellanuova, I., Fermo, I., Frölich, J. C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07217-8 · Cited by 1,087
Self-citationSchwedhelm, E., Maas, R., Freese, R., Jung, D., Lukacs, Z., Jambrecina, A., Spickler, W., Schulze, F., & Böger, R. H. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02990.x · Cited by 494
Self-citationTeerlink, T., Nijveldt, R. J., de Jong, S., & van Leeuwen, P. A. M. (2002) · Analytical Biochemistry · doi:10.1006/abio.2001.5575 · Cited by 417
Böger, R. H. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.10.2842s · Cited by 363
Self-citationThe l-arginine paradox: Importance of the l-arginine/asymmetrical dimethylarginine ratio
BODEBOGER, S., SCALERA, F., & IGNARRO, L. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.002 · Cited by 347
Metadata
- Authors
- KIELSTEIN, J. T., BÖGER, R. H., BODE-BÖGER, S. M., SCHÄFFER, J., BARBEY, M., KOCH, K. M., & FRÖLICH, J. C.
- Venue
- Journal of the American Society of Nephrology
- Published
- 1999-03
- Volume
- 10
- Issue
- 3
- Pages
- 594-600
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2151296579
- Cited by
- 361
- References
- 34
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Asymmetric Dimethylarginine Plasma Concentrations Differ in Patients with End-Stage Renal Disease: Relationship to Treatment Method and Atherosclerotic Disease. https://app.cochat.ai/papers/10.1681/asn.v103594
- The paper
- KIELSTEIN, J. T., BÖGER, R. H., BODE-BÖGER, S. M., SCHÄFFER, J., BARBEY, M., KOCH, K. M., & FRÖLICH, J. C. (1999). Asymmetric Dimethylarginine Plasma Concentrations Differ in Patients with End-Stage Renal Disease: Relationship to Treatment Method and Atherosclerotic Disease. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v103594
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
